Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mazdutide in Chinese Subjects With Moderate-to-Severe OSA and Obesity (GLORY-OSA)
NCT06931028Phase 3Recruiting
- Sponsor
- Innovent Biologics
- Start
- Jun 2025
- Primary completion
- May 2027
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of mazdutide in obstructive sleep apnea (OSA), obesity, sponsored by Innovent Biologics. Started Jun 2025; status: recruiting.
02
Drugs
mazdutide
03
Conditions
obstructive sleep apnea (OSA)obesity
Beyond the preview
Go deeper on NCT06931028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06931028.